National Institutes of Nursing Research, Bethesda, Maryland, USA.
Biol Psychiatry. 2010 Dec 1;68(11):999-1006. doi: 10.1016/j.biopsych.2010.07.033. Epub 2010 Oct 15.
Elevated levels of proinflammatory cytokines, especially interleukin-6 (IL-6), can mediate the greater risk for cardiovascular disease in individuals with posttraumatic stress disorder (PTSD), particularly in those with comorbid major depressive disorder (MDD). However, IL-6 levels are not consistently elevated in either PTSD or MDD. Although PTSD is associated with supersensitivity to glucocorticoids; prior studies have not evaluated the effect of comorbid MDD.
Serum IL-6 levels were measured hourly between 7:00 pm and 7:00 am in individuals with PTSD with comorbid MDD (PTSD + MDD) (n = 9) and compared with those with PTSD without MDD (PTSD - MDD) (n = 9) and nontraumatized healthy control subjects (n = 14). Group differences in serum IL-6, plasma adrenocorticotropic hormone (ACTH), and plasma cortisol response to 30 mg of intravenous hydrocortisone were evaluated using linear mixed models.
Only subjects with PTSD + MDD exhibited higher, overnight serum IL-6 levels compared with individuals with PTSD - MDD (p < .01) and healthy control subjects (p < .001). Peak overnight IL-6 levels positively correlated with severity of PTSD (r = .56, p < .01) and depressive symptoms (r = .54, p < .01). Hydrocortisone administration significantly reduced IL-6 levels in both PTSD groups; however, IL-6 levels in PTSD + MDD were higher than both PTSD - MDD (p < .05) and healthy control subjects (p < .01). Following hydrocortisone administration, there was a greater reduction in levels of ACTH in PTSD - MDD compared with control subjects (p < .01).
Sustained elevations of overnight IL-6 levels and relatively decreased sensitivity to hydrocortisone distinguish PTSD + MDD from PTSD - MDD. Novel strategies that decrease IL-6 levels offer a new direction in the prevention and treatment of PTSD and associated comorbid medical illnesses.
促炎细胞因子水平升高,尤其是白细胞介素-6(IL-6),可介导创伤后应激障碍(PTSD)患者发生心血管疾病的风险增加,尤其是合并有重度抑郁障碍(MDD)的患者。然而,PTSD 或 MDD 患者的 IL-6 水平并非一直升高。尽管 PTSD 与糖皮质激素超敏有关,但先前的研究并未评估合并 MDD 的影响。
在合并有 MDD 的 PTSD 患者(PTSD + MDD)(n = 9)和无 MDD 的 PTSD 患者(PTSD - MDD)(n = 9)以及未受创伤的健康对照者(n = 14)中,分别于晚上 7 点至早上 7 点每小时测量血清 IL-6 水平。采用线性混合模型评估血清 IL-6、血浆促肾上腺皮质激素(ACTH)和静脉注射 30mg 氢化可的松后血浆皮质醇对 IL-6 的反应的组间差异。
仅 PTSD + MDD 患者的夜间血清 IL-6 水平高于 PTSD - MDD 患者(p <.01)和健康对照者(p <.001)。夜间 IL-6 水平的峰值与 PTSD 严重程度(r =.56,p <.01)和抑郁症状(r =.54,p <.01)呈正相关。氢化可的松给药可显著降低两组 PTSD 患者的 IL-6 水平;然而,PTSD + MDD 的 IL-6 水平高于 PTSD - MDD(p <.05)和健康对照者(p <.01)。给予氢化可的松后,PTSD - MDD 患者的 ACTH 水平降低幅度大于对照组(p <.01)。
夜间 IL-6 水平持续升高和相对降低对氢化可的松的敏感性可将 PTSD + MDD 与 PTSD - MDD 区分开来。降低 IL-6 水平的新策略为 PTSD 及其相关合并症的预防和治疗提供了新方向。